Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.88 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.68 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.68 |
| ▸ | TK2 | O00142 | 2/20 | 0.63 |
| ▸ | TK1 | P04183 | 1/20 | 0.57 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.56 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.55 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.55 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.55 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.55 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2056544 | 0.95 | PYGM (0.97) | PYGMP2RY6P2RY14TK2TK1 | |
| SCHEMBL97335 | 0.95 | PYGM (0.97) | PYGMP2RY6P2RY14TK2TK1 | |
| SCHEMBL3412420 | 0.95 | PYGM (0.97) | PYGMP2RY6P2RY14TK2TK1 | |
| SCHEMBL12315567 | 0.95 | PYGM (0.97) | PYGMP2RY6P2RY14TK2TK1 | |
| SCHEMBL97336 | 0.95 | PYGM (0.97) | PYGMP2RY6P2RY14TK2TK1 | |
| SCHEMBL3389861 | 0.95 | PYGM (0.97) | PYGMP2RY6P2RY14TK2TK1 | |
| SCHEMBL654674 | 0.95 | PYGM (0.97) | PYGMP2RY6P2RY14TK2TK1 | |
| SCHEMBL2056540 | 0.95 | PYGM (0.97) | PYGMP2RY6P2RY14TK2TK1 | |
| SCHEMBL2579194 | 0.95 | PYGM (0.97) | PYGMP2RY6P2RY14TK2TK1 | |
| SCHEMBL5165189 | 0.95 | PYGM (0.97) | PYGMP2RY6P2RY14TK2TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115279415-A | Compositions comprising linear polyribonucleotides for protein modulation and uses thereof | 旗舰创业创新第六有限责任公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-112567038-A | Compositions comprising cyclic polyribonucleotides and uses thereof | 旗舰创业创新第六有限责任公司 | 2021-03-26 | — | — | CN | disclosed |
| US-10927383-B2 | Cas9 mRNAs | ETHRIS GMBH (DE) | 2021-02-23 | — | — | US | disclosed |
| US-20180163213-A1 | CAS9 MRNAS | ETHRIS GMBH (DE) | 2018-06-14 | — | — | US | disclosed |
| US-7371833-B1 | Nucleic acid molecules with specific recognition of native PrPSc, production and use | UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG (ZA) | 2008-05-13 | — | — | US | disclosed |
| EP-1889910-A2 | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex | SomaLogic, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| EP-0736105-B1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS | SOMALOGIC INC (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20040132067-A1 | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex | SOMALOGIC, INC. | 2004-07-08 | — | — | US | disclosed |
| US-6482594-B2 | Made by exposing nucleic acid candidate sequences having photoreactive groups to the target molecule, irradiating complexes formed to crosslink, and separating the crosslinked complexes and amplifying to give the ligands | SOMALOGIC, INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020106652-A1 | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex | SOMALOGIC, INC. | 2002-08-08 | — | — | US | disclosed |
| US-6291184-B1 | DETECTING TARGET MOLECULES IN A BIOLOGICAL SUBSTANCE ASSOCIATED WITH DISEASES BY EXPOSING SUBSTANCE TO A NUCLEIC ACID LIGAND THAT PHOTOCROSSLINKS TO A TARGET MOLECULE; IRRADIATING THE SUBSTANCE CONTAINING LIGAND, DETECT COMPLEXES | SOMALOGIC, INC. | 2001-09-18 | — | — | US | disclosed |
| US-6001577-A | SCREENING FOR LIGANDS ASSOCIATED WITH A DISEASE BY DETECTING LIGAND THAT PHOTOCROSSLINKS TO TARGET WITH PHOTOREACTIVE GROUPS FROM CANDIDATE MIXTURE, REMOVING ANY NUCLEIC ACIDS WITH AFFINITIES NOT ASSOCIATED WITH DISEASE, AND AMPLIFYING | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0736105-A4 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX | UNIV RESEARCH CORP (US) | 1998-10-28 | — | — | EP | disclosed |
| US-5763177-A | SELEX IS AN ACRONYM FOR SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT; USEFUL FOR DIAGNOSIS AND/OR TREATMENT OF DISEASES OR PATHOLOGICAL OR TOXIC STATES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| EP-0736105-A1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX | NeXstar Pharmaceuticals, Inc. (US) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995008003-A1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX | UNIVERSITY RESEARCH CORPORATION (US) | 1995-03-23 | — | — | WO | disclosed |